ClinicalTrials.gg
Not yet recruitingNCT07135973Updated Nov 10, 2026

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

A Phase 4 interventional study of Belumosudil in Chronic Graft Versus Host Disease, sponsored by Sanofi. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Updated Nov 10, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome — 7 open to participants now, 8 under way, 2 of them phase 3. belumosudil · Bronchiolitis Obliterans Syndrome.

Planned enrollment
9th of 14
26 · median 34
Started
2026
with 3 others
Phase 4
2 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
6 of 14
Sanofi

Among the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is one of 2 in phase 4, and was the 12th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

7 of the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About belumosudil

belumosudil: first FDA approval 2021 (REZUROCK), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.

Study details include:

  • The study duration will be up to 12 months per participant.
  • The treatment duration will be up to 24 weeks.
  • The number of visits will be 7.
03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients at least 12 years of age inclusive, at the time of signing the
  • Participants who had an hematopoietic cell transplantation (HCT)
  • Previously received at least 2 for cGVHD
  • Received therapy with a stable dose over the 2 weeks prior to screening
  • Had persistent cGVHD manifestations and systemic therapy was indicated
  • (if aged ≥ 16 years)/Lansky (if aged \<16 years) Performance Score of ≥ 60
  • Capable of giving signed informed consent as described in the protocol

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • ≤1.5 X 109/L
  • count ≤ 50 X 109/L
  • (ALT) and aspartate aminotransferase (AST) ≥ 3 X (ULN) (>5 × ULN if due to cGVHD)
  • Total ≥ 1.5 X ULN
  • (GFR) ≤ 30 mL/min/1.73m3
  • Positive surface antigen, or antibody or antibody at screening
  • ≤39% or has lung score of 3

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    belumosudil

    200 mg taken orally once daily with food for 24 weeks

    Drug: Belumosudil

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR445761, Rezurock

06

What researchers measure

Primary outcomes

  1. Drug related Grade ≥ 3 treatment emergent adverse events (TEAE)

    Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) during the treatment period (24 weeks)

    Time frame: From baseline to 24 weeks

Secondary outcomes

  1. Best overall Response (BoR)

    Best overall Response (BoR), defined as the proportion of patients who achieved complete response (CR) or partial response (PR) according to the NIH Consensus Criteria.

    Time frame: Baseline to end of study i.e. 12 months

  2. Duration of Response (DOR)

    Duration of Response (DOR) calculated from time of initial PR or CR until documented progression, death, or new systemic therapy.

    Time frame: Baseline to end of study i.e. 12 months

  3. Time to Response (TTR)

    Time frame: Baseline to end of study i.e. 12 months

  4. Response by organ system (including GSR)

    Time frame: Baseline to end of study i.e. 12 months

  5. Time taken for New Treatment (TTNT) or death

    Time frame: Baseline to end of study i.e. 12 months

  6. Failure-free survival (FFS)

    Time frame: Baseline to end of study i.e. 12 months

  7. Overall survival (OS)

    Time frame: Baseline to end of study i.e. 12 months

  8. Change in Corticosteroid dose.

    Time frame: Baseline to end of study i.e. 12 months

  9. Change in CNI dose

    Time frame: Baseline to end of study i.e. 12 months

  10. Symptomatic improvement from baseline during treatment based on Lee Symptom Scale

    defined as a ≥7-point reduction from baseline in total symptom score on a scale of 0 to 100 which measures the symptoms of chronic GVHD, with higher scores indicating worse symptoms

    Time frame: Baseline to end of study i.e. 12 months

  11. Pulmonary Function Test (PFT)

    Total lung capacity, Residual volume, Forced expiratory volume, Tidal volume

    Time frame: Baseline to end of study i.e. 12 months

  12. Number of participants with treatment-emergent adverse events [TEAEs], serious TEAEs, and adverse events of special interest (AESIs)

    Time frame: Baseline to end of study i.e. 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 16 phase 4 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 79. This study's planned 9 months is below that.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartEst.
Nov 20, 2026was Aug 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Mar 17, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 10, 2026→Nov 20, 2026
moved 2 times, Oct 23, 2026 – Nov 10, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedSymptomatic improvement from baseline during treatment based on modified Lee Symptom ScaleTime frame: Baseline to end of study i.e. 12 months
Oct 23, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Oct 30, 2026→Nov 20, 2026
    + 1 other change: verification date
  2. Oct 23, 2026
    Start date Aug 10, 2026→Oct 30, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedSymptomatic improvement from baseline during treatment based on modified Lee Symptom ScaleTime frame: Baseline to end of study i.e. 12 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135973
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Nov 20, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Mar 17, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion